Three randomised controlled trials demonstrated the clinical and radiological impact of mitoxantrone (MITOX) in patients with multiple sclerosis (MS), showing a reduction in the rate of relapse frequency, disability worsening and new active lesions on MRI during the period of treatment (6-24 months). [1] [2] [3] MITOX was approved by the FDA in October 2000 and in several European countries in 2002, for use every 3 months (12 mg/m 2 ) for worsening relapsing-remitting, secondary progressive and relapsing-progressive MS. In France, the drug was approved by the AFSAPPS in October 2003 in patients with aggressive MS, given as induction therapy monthly for 6 months. Aggressive relapsing-remitting MS was defined using the clinical and radiological inclusion criteria from the French and British (FB) MS trial 1 : at least two relapses with sequelae or an increase in the Expanded Disability Status Scale (EDSS) score of at least 2 points during the 12 months preceding the start of MITOX therapy and the presence of at least one gadolinium (Gd) enhancing lesion on MRI, performed during the 3 months preceding the start of MITOX therapy. The dose of MITOX was limited to 140 mg/m 2 in the USA and Europe and to 72 mg/m 2 in France due to its potential cardiac toxicity. Because of its potential haematological toxicity, white blood cell (WBC) count should be checked regularly for at least 5 years.
We previously reported 4 an observational study of 100 patients with aggressive relapsing-remitting MS followed for at least 1 year after the start of MITOX therapy (median duration 3.8 years). Here, we have updated data on the same cohort (100 patients completed at least 5 years of followup). Our observational study reflected clinical routine practice and complemented the results of the FB MS trial, 1 providing a description of the long term clinical effectiveness and safety profile of MITOX, and addressing some predictors of MITOX response.
MATERIAL AND METHODS Study population
From the Rennes's EDMUS (European Database for Multiple Sclerosis) database, 5 we enrolled the first 100 consecutive patients with aggressive relapsing-remitting MS who were treated with MITOX as induction therapy monthly for 6 months. Patients received their first course of MITOX between September 1992 and September 2000. Ten patients were included in the FB MS Trial. 1 The remaining 90 patients were given MITOX on the basis of criteria that were very similar to the pivotal study's inclusion criteria. It was necessary for women to be using effective contraception. therapy (from M212 to M0) and thereafter at least once a year over the period of follow-up. Effectiveness parameters (relapses, disability variations on the EDSS scale 6 and eventually occurrence of a secondary progressive phase) as well as safety data (echocardiogram and WBC counts performed before and then yearly for 5 years after MITOX treatment) were prospectively recorded in the EDMUS database.
Regarding MRI data, because of the methodological differences across our region (different MR field strength, different MR sequences), we retained as a single MR variable the presence of Gd enhancement.
In 92 patients, pretreatment MRI was performed at different time points: M0 for 20 patients, M23 to M0 for 47 patients, M23 to M26 for 16 patients and M26 to M212 for nine patients. Pre and post-treatment MRI were available for 76 patients (33 performed at the end of induction and 43 performed between M6 and M12).
Treatment
Patients received induction treatment according to the protocol of the FB MS trial, 1 including six monthly courses of MITOX 20 mg combined with methylprednisolone 1 g. When the WBC count (10 days after each course or just before a new one) was abnormal, the infusion dose was reduced to 10 mg (at least once in 46 patients). Treatment administration was shortened to 3 months in eight patients (seven because of an early favourable clinical and radiological response and one because of his cardiac background). The mean cumulative dose during induction was 65.7 (13) mg/m 2 . During the 12 months before MITOX treatment, 50 patients had not received any disease modifying therapy (ie, ''DMT naïve patients'') and 11 patients had received interferon beta (ie, ''IFN non-responders'').
As there was no prospectively planned therapeutic strategy after MITOX induction therapy, the choice of maintenance therapy was left to each patient's neurologist. Seventy-three patients systematically received maintenance therapy within 6 months of the last course of MITOX induction which was administered for at least 6 months. As firstline maintenance treatment, 21 patients received MITOX every 3 months (maximal cumulative dose 156 mg/m 2 ), 25 received IFN, 15 azathioprine, seven methotrexate and five glatiramer acetate. After the end of MITOX induction therapy, 27 patients received no DMT for a mean period of 3.3 years (range 1-7), and thereafter 13 of 27 patients took DMT as secondline therapy for at least 1 year.
Twenty-seven patients received several DMT at different time points over the following 5 years, generally when the disease was still active: new relapse within 6 months to 1 year (n = 5); within 122 years (n = 5); within 223 years (n = 3); within 324 years (n = 1); and within 425 years (n = 4).
Statistics
The magnitude of MS activity parameters was calculated yearly for the 5 years of follow-up and compared with corresponding levels or variations from M212 to M0. Comparisons were performed using relative risk and its confidence interval according to Woolf's method for the annual relapse rate (ARR), a test of comparison of means on paired samples for mean EDSS score and a x 2 test for the percentage of patients whose disease had worsened, stabilised or improved (change in EDSS score by at least 1 point, up to 5.5, or by 0.5 points over 5.5, confirmed at 3 months). The percentage of relapse free patients was calculated yearly and the time to the first relapse after the start of MITOX therapy was determined using the Kaplan-Meier method. 7 A McNemar x 2 test was used to compare the percentage of patients having Gd enhancing lesions on MRI before and after MITOX.
We looked for predictive factors of response to MITOX, such as demographic characteristics, pretreatment clinical and radiological activity, disability level at the start of MITOX therapy, non-response to IFN before MITOX, occurrence of a secondary progressive phase after MITOX treatment and need for rescue treatment with MITOX because of exacerbation of MS, using the Student's and x 2 tests for quantitative and qualitative variables, respectively.
Statistical analysis was performed using SPSS software for Windows and the level of significance was fixed at 5%.
RESULTS

Demographics and follow-up
The 100 consecutive patients with aggressive relapsing-remitting MS (77 females and 23 males) received their first course of MITOX at a mean age of 32.5 (9) years, 5.3 (5) years after the onset of MS (less than 1 year for 15 patients) (table 1). ARR, annual relapse rate; EDSS, Expanded Disability Status Scale; MITOX, mitoxantrone; MS, multiple sclerosis. *EDSS increased by 1.0 points or more up to an EDSS score of 5.5, and by 0.5 points or more for an EDSS score of .5.5, confirmed at 3 months after the onset of relapse. {Gd+, gadolinium enhancing lesions on MRI.
The cohort was followed for a median period of 6.8 years (2-13) after the start of treatment. Effectiveness and safety data for up to 5 years were available for 97 patients (one was lost to follow-up at 2.1 years after leaving our region and two patients died (suicide) at 2.1 and 4.1 years, respectively).
MS activity during the 12 months prior to MITOX
From M212 to M0, the 100 patients presented with 3.3 relapses per patient-year (table 1) . Their mean EDSS score increased significantly by 2.2 (1) points, with a mean EDSS score of 4.1 (1) at M0, and 88 patients ''worsened'' between M212 and M0. Worsening of disease was defined as a confirmed increase in EDSS score of at least 1 point (or 0.5 points for an EDSS score .5.5) 3 months after the start of relapse. Twelve patients were essentially ''stable'' during this period (mean EDSS 3.0 at M212 and 3.6 at M0), that is, there was no confirmed increase in EDSS score after 3 months, but as judged by their treating neurologist at the time of their relapse, they had a non-confirmed worsening of the EDSS score by at least 1 point. Furthermore, regarding their ARR (mean 3.1), four of the 12 patients had two severe relapses during the 12 months before inclusion and eight had at least three relapses during this period.
The 11 ''IFN non-responders'' worsened after 2-4 relapses (eight patients) or were stable but had presented with three or four relapses (three patients). Seventy-seven of 92 patients (84%) had Gd enhancing MRI lesions at baseline.
Short term impact on clinical and MRI MS activity parameters: results 1 year after the start of MITOX
The ARR decreased significantly from 3.3 (M212 to M0) to 0.30 during the first year of follow-up (p,10
26
), corresponding to a reduction of 91% in relapse frequency, with 78% of patients relapse free (table 2) . The mean EDSS improved significantly by 1.2 points, decreasing from 4.1 at M0 to 2.9 at 1 year (p,10 25 ). The proportion of patients with worsening disease decreased from 88/100 between M212 and M0 to 5/100 during the first year of follow-up (reduction of 94%). The latter five patients entered the secondary progressive phase of the disease a few months after starting MITOX therapy. The 95 remaining patients showed improvement (n = 64) or remained stable (n = 31) according to the EDSS scale.
The 12 patients with essentially stable EDSS scores during the 12 months preceding the start of MITOX therapy improved by 0.7 (1) points on the EDSS score.
The proportion of patients with Gd enhancing MRI lesions decreased from 65/76 (85.5%) before MITOX to 7/76 (9%) within 6 months of MITOX withdrawal (89.5% reduction) (x (table 2). The proportion of relapse free patients was 62% at 2 years, 42.5% at 3 years, 39% at 4 years and 32% at 5 years, and the median time to the first relapse after the start of MITOX therapy was of 2.72 years (mean 2.9 years; 95% CI 1.7 to 5.2). Compared with M0, the mean EDSS score remained significantly improved for up to 5 years of follow-up, with a score of 3.1 at 2 years, 3.3 at 3 years, 3.5 at 4 years and 3.6 at 5 years; p,0.008). The percentage of ''non-worsening'' patients from the start of MITOX treatment over the 5 years of followup remained greater than 60% (86% at 2 years, 71% at 3 years, 64% at 4 years and 60% at 5 years); these patients did not experience any further irreversible increase in disability, with a sustained benefit of MITOX induction therapy, following different maintenance treatment regimens. However, six of these patients were retreated with MITOX after exacerbation of disease (from 1 to 4.3 years after the first course of MITOX) with again a rapidly favourable evolution. Twenty patients developed a secondary progressive disease course 2.4 (1) years after the start of MITOX therapy. Examining the evolution of disease based on maintenance therapy started after MITOX induction, the heterogeneity of the data limited a straightforward comparison (data not shown). However, among the 73 patients who received maintenance therapy within 6 months after the end of MITOX induction therapy, the ARR for the following 24 months was significantly lower for the 21 patients treated with MITOX every 3 months (ARR = 0.09) than for the 52 patients treated with other DMTs (0.33-0.39) (p,0.01). Among the 27 patients who did not receive maintenance therapy within 6 months after the end of MITOX induction therapy, the ARR was 0.43 for the following 24 months. Beyond 2 years of follow-up, because of individual treatment changes, the data became increasingly heterogeneous, precluding further subgroup analysis for longer follow-up periods.
Predictors of MITOX response
Younger age and lower EDSS score at baseline were predictive of a better response to MITOX. Indeed, the percentage of ''nonworsened'' patients during the first and second years of followup was higher in the 62 patients with an EDSS score (4 at the start of MITOX therapy (100% at year 1 and 92% at year 2) compared with the 38 patients with an EDSS score .4 at the start of MITOX treatment (87% at year 1 and 74% at year 2) (p,0.007). The five patients who had a worsened disease course at 1 year (with an early conversion to a secondary progressive evolution) were older at the start of MITOX treatment than the 95 other patients (mean age 41 (6) vs 32 (1) years (p,0.02)) and had already accumulated more disability, with a mean EDSS score of 5.8 (1) versus 4.0 (1) at M0 (p,0.006). The 20 patients with a secondary progressive disease course 2.4 (1) years after the start of MITOX therapy had already accumulated more disability at baseline than the 80 MS patients who remained relapsing-remitting (mean EDSS score 4.8 vs 3.9) (p,0.01). In contrast, MRI activity and failure to respond to IFN beta before MITOX did not influence the response to MITOX: the 15 patients without Gd enhancing MRI lesions before MITOX had a reduction in ARR from 3.0 to 0.3 and improved their mean EDSS score by 1.0 points at 1 year. The 11 ''IFN non-responders'' and the 50 ''DMT naïve patients'' had similar demographics and disease activity parameters at the start of MITOX therapy (table 3) . They showed a similar degree of improvement (ARR reductions of 91% vs 93%, 80% vs 76% relapse free patients, decrease in mean EDSS score by 1.0 points, 55% vs 56% of patients ''improved'', 0% vs 6% of patients ''worsened'').
The duration of induction therapy did not influence the 1 year clinical and MRI results (data not shown). However, a MITOX rescue treatment because of exacerbation of the disease (12-52 months after the start of MITOX start) was administered more frequently in patients with a shorter MITOX induction period: five rescue treatments in eight patients with a 3 month induction versus 16 rescue treatments in 92 patients with a 6 month induction (p,0.001).
Safety profile
Among the 100 patients, three presented with an asymptomatic decrease in left ventricular ejection fraction of less than 50% 1 month, 1. Seven infectious episodes occurred during administration of MITOX: three associated with a severe neutropenia (,500/mm 3 ) and four without severe neutropenia. Moderate nausea was reported by 24% of patients and one presented with vomiting for several days after treatment, despite antiemetic medication. Grade I alopecia, reversible after the end of MITOX therapy, was observed in 32.5% of patients. Among the 70 women at risk of amenorrhoea (age (45 years with menstruations at the start of MITOX treatment), nine had transitory amenorrhea (13%) and seven reported persistent amenorrhea (10%) (five were aged more than 35 years at baseline). Fourteen women gave birth to 16 babies, all normal. Five patients died 2, 4, 5, 6 and 10 years after the start of MITOX therapy from suicide (first two cases), pulmonary cancer related to smoking abuse and severe disabling MS (last two cases). No death was MITOX related.
DISCUSSION
In this open study of 100 consecutive patients with an aggressive relapsing-remitting MS, monthly MITOX as induction therapy for 6 months induced a significant reduction in MS inflammatory activity parameters over the 12 months following the first course: relapse frequency was reduced by 91%, 78% of patients were relapse free and MRI activity was reduced by 89%. This strong and rapid impact on the inflammatory process was associated with an improvement in disability as the mean EDSS score decreased by 1.2 points, and 64% of patients improved by 1 point or more on the EDSS (confirmed at 3 months). These short term results were very similar to those of the FB MS trial 1 in which relapse frequency was reduced by 79%, MRI activity by 89% and 57% of patients improved by 1 point or more on the EDSS. Similar results were presented by Debouverie and colleagues 8 who showed, in addition, greater clinical benefit in patients with at least three relapses of different localisations and Gd enhancing lesions on MRI during the 24 months preceding MITOX therapy. Beyond 12 months after the start of MITOX therapy, ARR remained low for up to 5 years of follow-up (0.30-0.42), corresponding to a reduction of 90% compared with the 12 months preceding treatment, and the median time to the first new relapse was 2.7 years.
The efficacy of MITOX has never been strictly compared with the impact of other DMTs, and published data from controlled trials usually do not provide a sufficiently long follow-up period or a satisfactorily larger number of patients. However, examining the data published with other DMTs in relapsing MS (table 4) , our results suggest a stronger clinical impact of MITOX compared with IFN beta and glatiramer acetate on the usual parameters of inflammation (ARR, relapse free patients, time to first relapse). [9] [10] [11] [12] The impact of MITOX was similar to that of natalizumab. 13 However, in contrast with natalizumab whose effect on inflammatory markers disappeared after cessation of treatment, 14 our study favoured a prolonged effect of MITOX after the last course, as shown by others, 2 3 8 suggesting that MITOX may be a better candidate as induction therapy in MS.
Predictors of treatment response suggested that patients who worsened in the first year of treatment were already more disabled at the start of treatment. Furthermore, patients treated after reaching an irreversible EDSS score of 4 had a worse treatment response in terms of disability progression within 2 years after the start of MITOX therapy. These observations suggest a better beneficial effect of MITOX when given at an early stage of the disease, when focal neuroinflammation is still dominating. Similar observations were described with Campath-1h, with a higher positive impact on disease course when given to patients with an active and early relapsingremitting MS. 15 However, the potential toxicity of MITOX must also be taken into account when its indication is discussed at an early stage of the disease.
In our cohort of 100 patients, MITOX was generally safe. At a median cumulative dose of 75 mg/m 2 , we did not observe any case of acute heart failure. Ghalie and colleagues 16 reported two cases of acute heart failure in a cohort of 1378 patients, and one case 17 occurred among the French cohort of 802 MS patients followed yearly for at least 5 years (last update presented at the ECTRIMS in 2006 18 ). Recently, Goffette et al observed three cases of delayed congestive heart failure among 52 patients with MS treated with MITOX after a cumulative dose of 144 mg/m 2 , and two out of three patients were pretreated with cyclophosphamide. 17 We observed one case of acute leukaemia with an abnormal WBC count that prompted further diagnostic investigations and responded to specific treatment. This patient was one of two cases of leukaemia reported in the French cohort of 802 patients. 17 The relative risk (0.25%) in MS patients was lower than the risk observed in oncology patients who received MITOX in combination with other chemotherapies and radiotherapy. 19 These safety data emphasise the need to perform an echocardiogram yearly and WBC every 3 months for 5 years after the last course of MITOX, as recommended by the AFSAPPS, in order to diagnose as early as possible potential leukaemia before the appearance of clinical manifestations.
CONCLUSION
In our observational study of 100 consecutively treated MS patients, monthly infusions of MITOX for 6 months as induction therapy followed by maintenance treatment showed sustained clinical benefit for up to 5 years, with an acceptable adverse events profile in patients with aggressive relapsingremitting MS.
